Debiopharm
Chemin Messidor 5-7
Case Postale 5911
Lausanne
CH - 1002
Tel: 41-21-321-0111
Fax: 41-21-321-0169
Website: http://www.debiopharm.com/
213 articles about Debiopharm
-
Debiopharm Awarded $2.1 Million From CARB-X in the Fight Against a Highly Resistant Nosocomial-Pneumonia Causing Superbug
5/14/2019
The grant will support development of the Debio 1454 program to treat hospital-acquired pneumonia (HAP) caused by Acinetobacter baumannii
-
GenePOC Obtains CE Marked for its GenePOC™ Carba Test
4/11/2019
Third test to be CE marked, the GenePOC Carba assay, to be used with the revogene™ device.
-
Debiopharm Releases Results of 3 Key Oncology Compound Programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA
4/1/2019
Debiopharm announces the poster presentations of preclinical data for Debio 0123 and clinical data for Debio 1143 and Debio 1347
-
Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections
2/26/2019
This study, a randomized open-label active-controlled trial, will assess the safety, tolerability, and efficacy of afabicin IV/oral in the treatment of patients with bone or joint infection
-
Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II Study Evaluating Debio 1347 in Advanced Solid Tumors Harboring an FGFR fusion
2/14/2019
Patients will be recruited in North America, Europe, South America and the Asia Pacific region.
-
Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America
1/7/2019
Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees.
-
Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology
10/11/2018
Collaboration to pursue the development of a radioconjugated minigastrin analogue (Debio 1124) for cancer patients.
-
FDA Grants Fast Track Designation to Debiopharm International's Debio 1347 for the Treatment of Patients With Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration
5/8/2018
Debiopharm International SA announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Debio 1347, an FGFR 1-3 Inhibitor, for the treatment of patients with unresectable or metastatic tumors with a specific FGFR gene alteration.
-
Debiopharm International SA Strengthens Compliance and Clinical Trial Oversight With Veeva Vault eTMF
4/17/2018
Global biopharmaceutical company enables real-time inspection readiness and improves CRO collaboration
-
Debiopharm Continues the Fight Against Antibiotic Resistance With Investment in ABAC Therapeutics
2/15/2018
This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the fight against the worrying emergence of antibiotic resistance.
-
Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com
11/22/2017
he website provides patients and their caregivers with helpful information on Debiopharm's clinical trials and studies.
-
EMA Grants Orphan Drug Designation to Debiopharm International's FGFR Inhibitor Debio 1347 in the Treatment of Biliary Tract Cancer
11/14/2017
Debio 1347 is an orally available small molecule selectively targeting FGFR 1, 2, 3 signaling pathways and is currently tested in a phase I study in patients with FGFR genomically activated advanced solid tumors.
-
Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors Including NSCLC
11/6/2017
The trial is being conducted under a clinical collaboration agreement announced last year between Debiopharm International SA and the Merck-Pfizer Alliance.
-
Arbor Pharma And Debiopharm Announce Commercial Availability Of Triptodur, Triptorelin 6-Month Formulation, For Treatment Of Central Precocious Puberty (CPP)
10/3/2017
-
The Japanese Cancer Association And Debiopharm Announce Winners Of The 2017 JCA-Mauvernay Award
10/2/2017
-
Debiopharm Awarded $2.6 Million Grant From CARB-X To Support Development Of Debio 1453 To Fight Drug Resistant Gonorrhea
7/25/2017
-
Arbor Pharma And Debiopharm Announce U.S. FDA Approval For Triptodur, Triptorelin 6-Month Formulation, In The Treatment Of Central Precocious Puberty (CPP)
6/30/2017
-
Almac Discovery And Debiopharm Announce A Licensing Agreement For The Development Of A Novel Wee-1 Inhibitor
6/20/2017
-
Debiopharm Announces Completion Of Enrollment In Phase I/II Clinical Trial With Debio 1143 In SCCHN
6/15/2017
-
Debiopharm Announces Results From Phase I Dose-Escalation Study Of Debio 1347/CH5183284
6/1/2017